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A complement fixation test for mumps was first described by Enders and his 
coworkers (1, 2).  This test, which employed suspensions of parotid glands from 
monkeys infected with mumps virus, was found very useful since antibodies 
could be detected in all patients following an attack of the disease.  It proved 
particularly valuable as an aid in the diagnosis of some of the more unusual 
manifestations of infection with the virus of mumps, such as meningoencepha- 
litis in the absence of preceding or concurrent parotitis (3).  Extensive studies 
on the correlation between the results of the complement fixation test and re- 
sistance to mumps (4)  showed that the disease occurred practically always in 
individuals whose sera gave negative reactions prior to infection.  A positive 
test was obtained in 72 per cent of the subjects admitting parotitis at some time 
in the past.  It also was found positive in 42 per cent of individuals who failed 
to reveal previous attacks of mumps.  This finding, indicating the frequency of 
inapparent  infections with mumps  virus,  was  substantiated  by  the  demon- 
stration in  some exposed  individuals of the  formation of complement-fixing 
antibodies in the absence of clinical signs of disease. 
The adaptation of mumps virus to the chick embryo led to a  more readily 
available source of antigen (5, 6).  An analysis of various preparations of tis- 
sues and fluids derived from chick embryos infected with this agent revealed 
that  they contained at  least  two  serologicaUy  distinct complement fixation 
antigens (7).  One of these was found to be closely linked with the virus and 
present  predominantly in  the  amniotic and  allantoic fluids;  the  other  was 
smaller in size and demonstrable mainly in the  infected tissues; i. e.,  in the 
amniotic and allantoic membranes.  The virus-bound or "V" antigen could be 
differentiated from the smaller soluble or "S" antigen by serum cross-absorption 
technique, in that antibodies against V  could be removed from human con- 
valescent sera by absorption with this antigen, leaving most of anti-S in solution 
and,  conversely, absorption  with S  left antibodies against  V  in  the  serum. 
This observation of antigenic differences was confirmed by the fact that human 
sera  reacted  to  a  varying extent with S  and V  preparations.  The  antigen 
* The work  described  in this paper was aided by the Office  of Naval Research  and the U. S. 
Public Health Service. 
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derived from the infected monkey parotid gland, which had been used by the 
earlier workers, has not been compared as yet with the chick embryo materials. 
It is impossible, therefore,  to state definitely at present whether it contained 
measurable quantities of both the V and S antigens or only one of them.  Cer- 
tain of the observations to be described point to dominance of the S:antigen in 
suspensions of monkey parotid glands. 
It is the purpose of this paper to summarize the results of an extensive anal- 
ysis of the serological reactivity of human sara taken at various stages of infec- 
tion.  The results show that antibodies against S  antigen appear earlier, as a 
rule, than those against V, and that anti-V remains measurable usually for a 
longer period than anti-S.  Thus, it will be shown that both antigens have 
their place in the early diagnosis of mumps, whereas in the determination of 
susceptibility use of  the  V  antigen only appears  sufficient. 
Materials and Methods 
Preparation of Complement-Fixing  Anligens.--The egg-adapted strain of mumps virus used 
for the preparation  of antigens was obtained from Dr. John F. Enders in the 5th amniotic 
passage (6).  It has been adapted  to the allantoic sac of the chick embryo yielding allantoic 
fluids of high infectivity (i0 s ID~0/ml.).  The antigens were prepared from allantoic fluids 
and chorioaliantoic sacs of the 14th to 16th allantoic passages.  Suitable numbers of 8-day-old 
chick embryos were inoculated with 0.5 ml. of infected allantoic fluid diluted in broth to 
10  -2 to 10  -4.  The technic of inoculation has been described previously (7).  After 5 days of 
further incubation  of the eggs at 35--37°C.  the allantoic fluids as well as the allantoic sacs were 
harvested  aseptically.  The fluids containing the virus-bound antigen (V) were dialyzed in 
sterile cellophane bags against 20 volumes of ~x/100 phosphate-buffered saline of pH 7.0 in 
order to remove most of the urates prior to irradiation with ultraviolet  light by a technic 
previously described (8). 
The allantoic sacs were thoroughly washed in sterile buffered saline solution, drained on 
sterile filter paper, and weighe4.  A 20 per cent suspension in buffered saline solution was made 
by emulsifying the tissue in a Waring blendor for 3 minutes.  After preliminary centrifugation 
of the suspension at 2,000 R.P.~. for 10 minutes, the superuatant fluid was subjected to high 
speed centrifugation at 20,000 R.I~.~. for 20 minutes.  The supernatant fluid obtained after 
this centrifugation served as soluble (S) antigen. 
Control antigens were prepared according to the methods described above from uninfected 
chick embryos of the same age and usually from the same batch of eggs supplying the mumps 
preparations.  The normal allantoic fluid gave positive complement fixation tests with human 
sara only very rarely.  In these cases, the control antigens prepared from normal allantoie 
membranes, likewise, gave positive results.  The normal allantoic fluid was omitted, there- 
fore, in later tests. 
The dialyzed infected allantoic fluid was irradiated in order to inactivate the virus, and the 
membrane antigen was treated in the same way.  To all ~igens i: I0,000 merthiolate was 
added as a preservative.  They proved to be stable at 4°C. for at least 3 months. 
Human Scra.--Blood  was collected from patients  1 at varying stages  of infection with 
mumps virus and permitted to clot.  The serum was separated and inactivated at 60°C. for 
20 minutes.  In case reactions with the normal control antigen were encountered, a second 
1  The sara of 63 cases were studied in collaboration with Dr. Vers 01dfeld of the Epidemis- 
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heating of the sera to 60°C. for 20 minutes frequently decreased this reactivity (2)  but rarely 
removed it completely.  The sera were stored in the frozen state at  -10°C.  until used for 
the tests. 
Complement Fixation Test.--Twofold dilutions of the sera were prepared beginning with 
undiluted serum or 1:2 in cases where low or negative reactions were expected, and with 
correspondingly higher dilutions in convalescent specimens.  Of each dilution 0.1 ml. was 
transferred to 4 tubes each.  Thus, 4 series of increasing dilutions were obtained, the first set 
to receive saline solution (serum control); the second, mumps allantoic fluid (V antigen); the 
third, the superuatant fluid of normal aUantoic sac (N antigen); and the fourth, the super- 
natant fluid of mumps allantoic sac (S antigen).  The V and S antigens were used in optimal 
dilution; i.e., the dilution giving the highest titer with a  standard serum according to pre- 
liminary fitrations.  Such a  standardization test is shown in Table I.  The N  antigen was 
diluted to the same extent as the S preparation, both showing approximately the same amount 
of nitrogen and  phosphorus.  Each  antigen dilution was mixed with an  equal volume of 
TABLE  I 
OptimalTitratio~  ~Sand V Antig~sand Convalesc~tSerum 
Serum  S antigen  V antigen  Sa- 
112  line 
Und.  1:2  1:3  1:4  1:6  1:8  1:12  1:16  1:24  1:32  1:48  Und.  1:2  1:3  1:4  1:6  I:8 
C  1:32 
1:64 
1:128 
1:256 
1:512 
1:1024 
0  0  0  0  0  0  0  0  0  0  wk 
0  0  0  0  0  0  0  0  0  0  st 
0  0  0  0  0  0  0  0  (0)  wk  ac 
ac  wk  (0)  (0)  0  0  (0)  tr  wk  st  c 
c  c  c  (c)  (c)  (c)  (c)  c  c  c  c 
C  C  C  C  C  C  C  C  C  C  C 
SaHne  c  c 
0  0  0  0  (0)  tr 
0  0  0  0  (0)  tr 
0  0  0  0  (0)  wk 
(0)  0  0  (0)  wk  ac 
tr  0  0  tr  st  (c) 
ac  ac  ac  c  c  c 
0  =  no hemolysis; tr =  trace; wk  --- weak; st =  strong; ac =  almost complete; c  -- complete 
hemolysis. 
suitably diluted guinea pig complement and the mixture was then added to the corresponding 
tubes, in 0.2 mI. amounts.  In large tests the antigen-complement mixtures were added by 
means of an automatic pipette.  Sharp and Dohme "Lyovac" complement was used through- 
out3  It was adjusted to contain 1.5 minimal hemolytic units per 0.1 ml.  After the primary 
incubation of the test at 37°C. for i  hour, 0.2 ml. of sensitized sheep ceils (2.5 per cent) was 
added by automatic pipette.  The test was further incubated at 37°C. for 1 hour when read- 
ings were recorded.  The last dilution of serum giving complete fixation of  complement (no 
hemolysis) was considered to be the end point.  All antibody titers are recorded as the initial 
dilution of serum.  Known positive sera were included in all tests. 
EXPERIM~ENTAL 
The Antibody Response Following  Experimental Exposure to Mumps Virus.- 
In order to  study  the  development of antibodies to  the  two  antigens in  the 
course of infection with mumps virus, it was felt that experimental exposure 
of man to this agent would yield more dependable data, since the time of expo- 
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sure would be accurately known.  Sera of such experimental cases were avail- 
able from studies for other purposes  which will be  reported separately  (9). 
Fig. 1 demonstrates graphically the results of complement fixation tests with the 
V  and S  antigens and sera taken from a  number of representative cases at 
varying intervals after experimental exposure to an oral spray of three different 
virus preparations.  Cases F.G. and G.C. had been exposed, with other indi- 
viduals, to 5th passage amniotic fluid infected with a  strain of mumps virus 
(J.P.), which had been isolated directly in eggs by the amniotic route from the 
spinal fluid of a patient with meningoencephalitis (10).  F.G.  and others not 
shown in the figure developed parotitis on about the 18th day after exposure; 
G.C. failed to do so and remained apparently well.  On comparing the  sero- 
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T~x~-FTo. 1.  Development of antibodies following experimental exposure to mumps virus. 
logical results, it can be seen that both individuals developed antibodies  to 
about the same extent, although only one became clinically ill.  This result 
appears comparable to subclinical infections encountered under epidemic con- 
ditions (2, 4, 11).  In both cases, antibodies to S antigen appeared earlier and 
reached high levels before anti-V commenced to rise.  It should also be noted 
that anti-S had already reached a high titer at the time parotitis became mani- 
fest. 
Cases E.C., J.J., and C.H. were exposed to 16th passage aHantoic fluid of the 
strain of virus received from Dr. Enders; i. e., the same agent which was used 
for the preparation of the antigens.  These subjects, as well as several others 
not shown in the figure, failed to develop clinical signs of mumps.  This strain, 
therefore, may be considered attentuated in regard to its pathogenicity for man. 
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cases exposed to the virulent strain of virus.  The lag in the development of 
anti-V was quite marked  in case E.C.,  and patient J.J. failed altogether to 
develop a significant level of this antibody.  The serological response of patient 
C.H., on the other hand,  was practically indistinguishable  from that  of the 
cases F.G., and G.C., exposed to the virulent virus.  Finally, the sixth patient, 
L.H., serves as an example of several cases exposed to infected monkey parotid 
gland, supplied by Dr. J. F. Enders.  In this patient, parotitis developed on 
the 20th day after exposure,  at a time when both these antibodies were as yet 
low in titer.  Again anti-S appeared somewhat before anti-V.  The difference 
between these two antibodies might have been more strikingly demonstrable 
if sera had been available between the 22nd and 32nd days after exposure. 
The Antibody Response Following Natural Infection.--Sera from cases of the 
natural  disease  during  the epidemic of 1946-47  could be collected only after 
appearance of symptoms.  The date of onset was supplied by the parents and 
its accuracy was possibly influenced  by their vigilance.  The serological  data 
RNTI'S  • 
A~i-~ ....... 
P 
13~  9  56  LI  15  ~'6  10  ;~46  10  135  9 
t 
~I~.~S  ~F%er onse% of ~tnp~ms 
TZXT-Fm. 2, Development of andbo~es ~n epide~c cases  of mumps. 
obtained in many of these cases demonstrate that the antibody response in the 
natural  disease  is similar to that encountered after experimental exposure to 
the virus, as shown in Fig. 2 (cases 47, 49, and 89).  The antibodies against S 
usually rise prior to those against V.  In some of the cases, the first serum may 
have been taken too late to show this difference clearly,  as in case 38, but the 
slope of the respective antibody curves indicates that anti-S may have been 
exceeding anti-V prior to the date of the first bleeding.  Finally,  case 53 is 
included to show that in some patients anti-V may develop simultaneously with 
anti-S  or even prior  to the latter. 
These data demonstrate that the reactivity of sera taken in the first few days 
of illness frequently is restricted to interaction with the S antigen.  As a rule, 
this reaction leads to complete fixation  of complement in all tubes up to the 
second last effective dilution  of serum," the last giving  only partial  fixation. 
On occasions, however, the reactions with S antigen show marked zoning,  and 
only partial fixation of complement, over a wide range of serum dilutions.  This 
phenomenon has been observed previously by Enders,  Cohen,  and Kane (2), 
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this activity are listed in Table II.  Sera taken later in the disease always show 
the usual complete fixation of complement over a  series of dilutions and partial 
fixation in only one or two further tubes.  This reactivity of early sera is con- 
sidered significant but its interpretation is not yet clear. 
The frequency with which these antibody relationships are encountered may 
be  gleaned from  Fig.  3.  In  this  figure  results  are  collected of  complement 
TABLE II 
Cases of Mumps Showing Zoning and Partial Fixation of Complement with S  Antigen in the 
First Days after Onset 
Instltu-  Patient No] 
tion 
D  77 
D  55 
H  131 
H  154 
H  153 
S  189 
S  168 
S antigen 
Time  Onset of  after 
disease  Dilution of serum  onset 
t:2  1:4  1:8  1:16  1:32  1:64  1:128  1:256 
1947  days 
3/9  2  st  wk  wk  ac.  (c) 
19  0  0  0  (0)  wk 
2/17  1  c  st  tr  wk  c 
28  0  0  0  0  (0)  c 
t  4/11  4  wk  tr  0  0  0  0 
7  0  0  0  0  0  0 
4/26  2  ac  st  wk  ac  (c)  c 
4  st  wk  tr  (0)  tr  ac 
6  (0)  0  0  (0)  wk 
4/25  1  wk  tr  (0)  (0)  (0)  st 
3  0  0  0  0  0  0 
4/12  0  wk  wk  st  st  ac 
11  0  0  0  tr  wk 
i 
3/30  4  t  tr  tr  tr  tr  wk  ac 
19  i  0  0  0  0  a¢ 
V antigen 
Serum titer 
0 
32 
0 
256 
8 
32 
0 
<2 
<2 
64 
8 
256 
fixation tests with several hundred sera.  Each dot represents one serum show- 
ing the liter of antibodies against S on the ordinate and that against V  on the 
abscissa.  The sera are grouped according to the time they were taken after the 
reported day of onset of mumps.  It can be seen that in the Ist week of illness, 
most  of the  dots lie above  the diagonal line,  indicating that  anti-S  exceeds 
anti-V.  In the first 3 days some of the sera have no antibodies against either 
S  or V; many have no or low anti-V but already high anti-S antibodies; some 
are high in both,  and in only a  few  the anti-V antibodies exceed the anti-S. G.  HENLE~  S.  HARRIS~  AND  W.  HENLE  139 
From 4 to 7 days after onset, only very few of the patients fail to reveal signifi- 
cant levels of antibodies against both antigens.  The incidence  of cases with 
high titers against S but low levels of antibodies against V has decreased.  From 
8  to 28 days after onset practically all cases possess high levels of antibodies 
against V and S.  Of the sera charted almost all had reached titers against the 
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TF4~T-Fto.  3.  Correlation  between  antibody  levels against  S  and  V  antigens at  various 
times after onset of mumps. 
S  antigen of 1:16 or higher, and most of them attained similar levels when 
tested with  the  V  antigen.  Thereafter the  antibodies  begin  to decrease in 
titer, the S antibodies usually at a  somewhat faster rate than those reacting 
with V.  If sera are analyzed, which were collected 6 months to several years 
after infection with mumps virus, it can be seen that in practically all of them 
anti-V exceeds anti-S.  The latter antibody may be low or absent in sera which 
show relatively high levels of anti-V.  The sera of certain patients analyzed 
several years after an established infection with mumps virus show no detect- 
able antibodies against either antigen. 140  MUMPS  COMPLEMENT  I~IXATION  TESTS 
In a comparison of results from uncomplicated cases of mumps with those of 
patients  showing  complications, such  as  meningoencephalitis, orchitis,  pan- 
ereatitis, and others, no significant qualitative differences became apparent but 
the levels of antibodies tended to be higher in such patients.  This difference 
was about twofold when the geometric mean antibody levels were calculated 
for the two groups.  Since only few complications were encountered during 
the mumps epidemic of 1946-47,  further observations are required to ascertain 
whether or not there is a significant relationship between the time of appear- 
ance of antibodies and their concentration on the one hand, and the develop- 
ment of complications on the other. 
The ROle of the V and S Antigens in the Diagnosis of Mumps.--A summary of 
the data presented, thus far, provides a diagnostic scheme as shown in Table 
IIL  If the serum of a patient has a high titer against the S antigen (1:16 or 
higher) and few or no antibodies against V,  the present illness is probably 
TABLE  III 
Tentative interpretation of Serological Results 
Anti-S titer 
~gh 
High 
Low or absent 
Anti-¥ titer 
Low or absent 
~ngh 
Positive to varying extent 
Jnterpretstion 
First days of disease 
Recent apparent or inapparent infection, 
or  current  mumps  of  several  days' 
duration 
Long  past  apparent  or  inapparent 
infection 
caused by mumps virus.  High levels of both antibodies indicate a recent or a 
current  attack  of  several days' standing.  Little or no anti-S,  and distinct 
levels of anti-V (1:2 or higher) are considered signs of long past infection.  The 
table provides certain criteria for diagnosis which must be interpreted in the 
light of the individual patient. 
It has already been pointed out that the order of events in the first days of 
illness does not always conform to the presented picture, but it does so'suffi- 
ciently often to permit the early diagnosis of certain clinical manifestations, 
such as mumps meningoencephalitis in the absence of preceding or concurrent 
parotitis.  Table  IV shows serological data obtained in  12  cases of mumps 
meningoencephalitis in which parotitis was absent or developed at a later date 
(case L.H.)?  In 8 of the 12 cases, the finding of high anti-S and low anti-V 
levels provided aserological diagnosis of mumps early after onset.  Six of these 
8 cases from whom a second serum specimen was obtained at a later date showed 
, The sera of 2 of these cases (L.M., and M.D.) were submitted by Dr. A. J. Rhodes, of the 
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TABLE IV 
Early Diagnosis  of Mumps  MeningoEncephalitis  urithou~ Tarotitis by Comflement Fixation 
Tests with S'and V Anti ens 
Serum titer 
Patient  rime after onsel  ~s.  Remarka 
S antigen  V antigen 
H.C.  256 
L.H. 
C.B. 
M.D. 
J.p. 
D.L. 
.Nys. 
J.S. 
Ahr. 
Mar. 
A.P. 
Wri. 
days 
8 
15  512  I 
6  64 
13  64  I 
4  32 
18  64 
2  64  ] 
14  32  l 
2  16 
2  16 
15  64 
2  256 
6  64 
19  128 
4  4 
18  16 
3  4 
15  16 
2  4 
6  4 
10  8 
17  16 
2  <2 
12  128+ 
8 
32 
4 
64 
<4 
64 
4 
128 
<2 
<2 
256 
<4 
64 
<2 
16 
2 
64 
4 
8 
32 
128 
4 
128+ 
Parotitis on 14th day 
No second serum, virus isolated 
from spinal fluid 
No second serum 
Virus isolated from spinal fluid 
subsequent rises particularly in anti-V.  From the spinal fluid of one of the 2 
patients from whom a  second serum could not be obtained, mumps virus was 
isolated.  This confirmed the result of the complement fixation test (10).  The 142  MUMPS COMPLEMENT FIXATION TESTS 
serological diagnosis of the remaining 4  cases listed in Table IV depended, as 
in the studies of Kane and Enders  (3), on the demonstration of rises in anti- 
bodies over a  period of 1 week or longer.  Significant rises in antibodies were 
measured  with  both  antigens.  In  several additional patients with  meningo- 
encephalitis, the first available sera were  taken rather late in the disease and 
yielded high titers against both V  and S  antigens.  In these, no rises in anti- 
bodies could be measured  and  thus definite proof was  not  obtained that  the 
neurological signs were a  result of infection with mumps virus. 
TABLE V 
Antibody Response Following Subcutaneous Vaccination or Skin Testing 
Ca~ 
No. 
Vaccination 
Anti-V  Anti-S 
A 
1  0 
2  0 
3  0 
4  2 
5  2 
6  2 
7  2 
8  2 
9  2 
10  2 
ll  2 
12  4 
13  6 
B 
0 
0 
6 
48 
48 
24  I 
24 
128 
8 
96 
128 
A  B 
0 
0 
0 
<2 
0 
<2 
<2 
0 
0 
<2 
0 
<2 
3 
0 
0 
3 
12 
32 
4 
2 
8 
~.2 
6 
24 
16 
8 
Case 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
Skin testing 
Anti.V  Anti-S 
A  B  A  .. 
0  0  0 
0  0  0 
0  8  0  I 
0  32 
0  32 
<2  4  <2 
<2  16  <2 
<2  32 
<2  32  <2 
<2  64 
2  32  <2 
2  16 
4  16 
4  32 
A -- serum taken before vaccination or skin test. 
B  =  serum taken 2 weeks after vaccination or skin test. 
The Antibody ResPonse Following Vaccination and Skin Testing.--It has been 
shown by others that both vaccination of monkeys and man with inactivated 
mumps  virus  (12-14)  and  skin  tests  in  man  (2,  15)  performed with  mumps 
antigen, caused the formation of complement fixing antibodies.  These obser- 
vations were confirmed in a  study of a  number of eases of each type.  Centri- 
fugally concentrated virus served as vaccine and infected allantoic fluid as skin 
test  material.  The  virus  in  both  instances  was  inactivated  by  ultraviolet 
irradiation.  Table V  summarizes the data selected from representative groups 
which show the variabifity of the response.  The results obtained following the 
two  types of stimuli were  very similar.  As a  rule,  the antibodies against V 
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these cases a restimulation of antibodies is indicated by the fact that low levels 
of anti-V were found in many of the sera taken before the skin test or before 
vaccination, a  finding compatible with past apparent or inapparent infection. 
Among those cases whose sera did not react with V antigen prior to vaccination 
or skin testing, some responded with the formation of antibody, others did not. 
Whether those who responded had lost their antihodies in the years following 
infection, and whether their reaction must therefore be classified as restimula- 
tion, or whether the response represents antibody formation de novo, cannot be 
stated at present. 
Non-Specific  Reactions.--The  reactions obtained with  these antigens in the 
majority of the sera studied appeared specific in that the sera failed to react 
with control antigens.  However, sera were encountered, on occasion, which 
gave positive complement fixation tests with suspensions of normal allantoic 
membrane.  These occurred in spite of heating  to  60°C. for 20 minutes.  A 
second heating  to 60°C.  (2)  removed  some,  but not all,  of the  non-specific 
reaction.  This reactivity with control antigen affected particularly the inter- 
pretation of the reactions with S antigen and not so much those with V antigen. 
Absorption of such sera with particulate components of normal allantoic sacs 
sedimentable  at  20,000  I~.P.M., removed  this  reactivity  and  uncovered  the 
specific reaction with the S preparation.  Table VI demonstrates several such 
experiments.  As can be seen, the three serum specimens obtained from case 
64 all reacted to about the same extent with N  antigen.  After absorption this 
reactivity was  lost,  whereas  the  reaction  with  the  S  preparation,  although 
reduced by  the  absorption,  showed  the  expected characteristic  rise  in  titer 
during the first few days of parotitis.  The reaction with V was not measurably 
affected by the absorption, nor was the Wassermann reaction.  The latter was 
apparently a  false positive, inasmuch as it became negative during convales- 
cence (16).  Case 67 gave essentially similar results except that a true positive 
Wassermann test was encountered in this patient.  Case 46 is included to show 
that  absorption  with  normal  membrane  particles  does  not  affect  the  titer 
against S antigen in sera which fail to show a reaction with N. 
The absorption experiments seemed to indicate that  antibodies  to normal 
chick components may occur in man on occasion and that Wassermann antigen 
is not involved in this reaction.  To elucidate this question further, sera were 
obtained from 6  luetic patients with no recent history of mumps.  None of 
these reacted with the normal membrane antigen and 4  were free of specific 
mumps antibodies.  These data suggested, on the other hand, that heterophile 
antibodies, possibly related to Forssman antibodies, might be responsible for 
some of the non-specific reactions.  This possibility was further supported by 
the observations that the sensitized sheep cells in the complement fixation test 
were agglutinated by some of the sera in the lower dilutions.  Absorption of 
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TABLE  VI 
Removal of Non-Specific Reactions by Absorption with Particulate Components Derived  from 
Normal Allantoic Membranes 
Case No. 
64 
67 
History 
Pansinusitis  3/9 
Parotifis 3/13  3/15 
Lues.  Skin test for 
mumps 3/15 
46  Parofitis 3/3 
"  I  Antibody tlters 
Date of  l?reatment  I  vs.  Wasser- 
bleeding  reaction  of serum  _  ___  mann 
__  N antigen  S  antigen  _V antigen 
1947  --  ]  1:32  1:32  1  1:16  + 
3/13  Absorbed  <1:4  1:8  1:16  + 
--  [  1:32  1:32  1:64 
Absorbed[  --  1 : 8  1: 64 
] 
--  /  1:32  1:64  :  1:128 
3/18  Absorbed[  --  1:32  [  1:128 
--  1:16  1:16  1:4  + 
3/15  Absorbed  1: 2  1:4  1 : 4  + 
--  1:16  1:32  1:128  + 
3/31  Absorbed  < 1:4  1 : 16  1:128  + 
--  <1:2  1:32  <1:2 
3/4  Absorbed  --  1:32  <1:2 
--  --  1:128  1:24  -- 
3/8  Absorbed  --  1:128  1:32  -- 
3/12  --  --  1:128  1:128 
Absorbed  --  1:128  1:128 
TABLE  VII 
Removal of Non-Specific  Reactions by  Absorption  with  Sheep  Erythrocytes 
Case No, 
D4 
History 
Positive 
(parotitis 3/7/47) 
D7  Negative 
51 
Positive 
(parotitis 2/28/47) 
Date  of 
bleeding 
1947 
3/7 
3/21 
3/3 
3/17 
Treatment  of 
serum 
Absorbed 
Absorbed 
Absorbed 
Absorbed 
Antibody fite~ 
N antigen  antigen 
1:64  1:64 
<1:4  <1:4 
1:32 
<1:2 
1:8 
0 
IV antigen 
1:4 
0 
1:64  1:54 
1:32  1:64 
1:8 
0 
1:64  1:32 
1:64  1:32 G. HENLE, S. KARRIS, AND W.  HENLE  145 
reactivity, whereas  absorption  of specific mumps convalescent  sera revealed 
that the mumps antibodies were not affected by such procedures.  Table VII 
shows some examples of this kind. 
DISCUSSION 
The data presented show that sera obtained from human beings at various 
stages of infection with the virus of mumps may differ distinctly in their content 
of antibodies against the two antigens,  the virus particle (V) and the soluble 
antigen (S).  In the early days of disease, anti-S antibody may reach high 
titers, whereas  anti-V may still be  low or absent.  This has permitted the 
serological recognition of an infection with mumps virus,  on occasion, on the 
1st  or 2nd  day of illness.  This presumptive test has been  confirmed in all 
instances  studied by the demonstration of rises in  antibodies  in subsequent 
sera.  It was found of great assistance in the early diagnosis of several cases of 
mumps meningoencephalitis  in the absence  of parotitis. 
For determination of resistance to mumps, use of the V antigen alone appears 
sufficient.  Many more individuals,  who experienced either apparent or inap- 
parent infections at some time in the past, will react with V than with S.  The 
r61e played by anti-V in the resistance of an individual to mumps has not been 
definitely established.  However, as has been shown (11), in a small group of 
children, no cases of mumps occurred among those giving significant reactions 
with V prior to an epidemic.  On the other hand, not all of the children whose 
sera failed  to react with V developed clinical or subclinical infections.  This 
latter observation  may depend upon several possible factors: (a) the intimacy 
of exposure may vary; (b) amounts of anti-V too small to measure may, never- 
theless, give protection, and (c) an antibody different from that measured by 
the described  complement  fixation technic  may be responsible for resistance. 
A comparison of the data published by Enders and his coworkers (1-4), with 
those  presented above,  indicates  that the antigen in suspensions of infected 
parotid glands of the monkey is dominantly of the S type.  This suggestion is 
based particularly upon the fact that-the marked zoning and the  incomplete 
fixation of complement with occasional sera of the early acute phase which have 
been observed using monkey antigdn were also found to occur employing the S 
antigen of the chick embryo, but not the V preparation.  This suggestion is in 
line too with the finding of high antibody  levels against monkey  parotid antigen 
in some other patients on the first few days of disease.  The monkey antigen, 
as prepared,  contains virus particles.  Whether the amount of it is sufficient to 
be reactive in the complement  fixation reaction cannot be stated until strict 
comparisons  are made of the various preparations of antigen with suitable 
immune sera. 
The serological response obtained under conditions of experimental  infection 
with a human pathogenic strain of mumps virus appeared to be similar to that 146  MUMPS  COMPLEMENT  FIXATION TESTS 
of the epidemic illness in every respect studied.  Furthermore, the exposure 
of human beings to "attentuated" mumps virus gave, in most instances, anti- 
body levels against V and S antigens comparable to those seen in uncomplicated 
cases of the natural disease.  These data seem to indicate, therefore, that such 
a procedure may lead to an enduring immunity, a suggestion which has already 
been explored  (17)  and which will be investigated further. 
Intradermal or subcutaneous injection of inactivated mumps virus has been 
shown in the past to stimulate formation of complement-fixing antibodies (2, 
12-15).  The present studies revealed that frequently only anti-V was formed. 
If anti-S also developed, its titer constituted, as a rule, only a fraction of that 
measured against V.  Antibody formation in these cases was noted particularly 
if the treated individual already possessed some antibodies, whereas only part 
of those with negative complement fixation tests responded to such stimuli.  It 
is possible that in these instances too the rise in antibodies was the result of 
restimulation by small quantities of antigen, wl~ereas for the de novo formation 
of antibodies, possibly more concentrated preparations of virus may be needed. 
These relationships call for further analysis. 
SUMMARY 
Human sera taken at various stages of mumps have been analyzed in regard 
to their reactivity with two serologically distinct complement fixation antigens 
which were derived from the infected chick embryo.  Antibodies to the soluble 
or S antigen appear earlier in the disease and, as a rule, reach high levels before 
antibodies against the virus-bound or V antigen commence to rise.  In early 
convalescence,  both  antibodies  reach  high  levels.  Subsequently  antibodies 
against the S antigen decrease usually at a faster rate than those against V, so 
that after a period of several years, frequently only anti-V may be left. 
These findings were found helpful in diagnostic procedures.  The use of both 
the V  and S antigens has permitted the early diagnosis of manifestations of 
mumps in the absence of parotitis, such as meningoencephalitis, since the finding 
of high levels of anti-S and of low titers of, or no, anti-V is considered diag- 
nostically significant for the first few days of illness.  For the determination of 
resistance the use of the V antigen appears more useful. 
Following vaccination or skin testing, antibodies against both antigens may 
develop; those against V increase more regularly and to higher titers than those 
against S. 
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